CIPLA LTD vs POLY MEDICURE LIMITED

A side-by-side comparison of CIPLA LTD (CIPLA) and POLY MEDICURE LIMITED (POLYMED) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, CIPLA LTD leads CIPLA vs POLYMED on 10 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

29.54
P/E ratio
52.88
3.42
P/B ratio
5.66
0.90%
Dividend yield
0.21%
₹48.02
EPS
₹31.78

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

11.60%
Return on equity
11.20%
15.00%
Return on capital
14.00%
21.00%
EBITDA margin
24.00%
13.71%
Net margin
17.12%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

7.37%
Revenue CAGR (3Y)
18.92%
10.88%
Profit CAGR (3Y)
21.49%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.15L Cr
Market cap
₹17,033 Cr
₹28,163 Cr
Revenue
₹1,875 Cr
₹3,862 Cr
Net profit
₹321 Cr
0.02
Debt / equity
0.11
CIPLA LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
  • ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.34%"]
POLY MEDICURE LIMITED
  • + ["Company has delivered good profit growth of 19.4% CAGR over last 5 years"]
  • ["Debtor days have increased from 83.8 to 103 days.", "Working capital days have increased from 126 days to 249 days"]
CIPLA LTD full analysis POLY MEDICURE LIMITED full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

CIPLA LTD vs POLY MEDICURE LIMITED: Share Price, Valuation & Which to Buy | DocStoX